KYMAB
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom.
KYMAB
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2010-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.kymab.com
Total Employee:
101+
Status:
Active
Contact:
44 1223 833301
Total Funding:
229.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Mobile Non Scaleable Content
Similar Organizations
Adamis Pharmaceuticals
Adamis Pharmaceuticals is a biopharmaceutical company developing therapeutics for respiratory diseases and cancer.
CureVac
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Innovent Biologics
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
Nautilus Biotech
Nautilus Biotech is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Board_member
2012-09-01
Current Employees Featured
Jasper Clube Senior Vice President, Intellectual Property & Chief Patent Council @ Kymab
Senior Vice President, Intellectual Property & Chief Patent Council
2010-08-01
Brandon Lewis Head of Corporate Strategy and Investor Relations @ Kymab
Head of Corporate Strategy and Investor Relations
Anne Hyland Chief Financial Officer & Company Secretary @ Kymab
Chief Financial Officer & Company Secretary
Nigel Clark Senior Vice President, Business Development @ Kymab
Senior Vice President, Business Development
Paulette Alexander Office Manager @ Kymab
Office Manager
2010-04-01
Allan Bradley Chief Scientific Officer @ Kymab
Chief Scientific Officer
2010-07-01
Founder
Investors List
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - Kymab
Malin Corporation
Malin Corporation investment in Series C - Kymab
Woodford Investment Management
Woodford Investment Management investment in Series C - Kymab
Wellcome Trust
Wellcome Trust investment in Series C - Kymab
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Series C - Kymab
Hepalink
Hepalink investment in Series C - Kymab
ORI Capital
ORI Capital investment in Series C - Kymab
Malin Corporation
Malin Corporation investment in Series B - Kymab
Woodford Investment Management
Woodford Investment Management investment in Series B - Kymab
Wellcome Trust
Wellcome Trust investment in Series B - Kymab
Official Site Inspections
http://www.kymab.com Semrush global rank: 3.64 M Semrush visits lastest month: 3.91 K
- Host name: 178.62.11.133
- IP address: 178.62.11.133
- Location: London United Kingdom
- Latitude: 51.5353
- Longitude: -0.6658
- Timezone: Europe/London
- Postal: SL1
More informations about "Kymab"
Kymab - Crunchbase Company Profile & Funding
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using …See details»
Kymab - Products, Competitors, Financials, Employees, …
Kymab operates as a clinical-stage biopharmaceutical company developing a deep pipeline of human antibody-based therapies in a broad range of indications. Use the CB Insights Platform …See details»
Kymab Limited - Devex
Learn more about Kymab Limited's jobs, projects, latest news, contact information and geographical presence. Kymab is discovering and developing fully human monoclonal …See details»
Sanofi to Acquire Kymab, Adding KY1005 to Pipeline | Sanofi
Jan 11, 2007 About Kymab. Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune mediated diseases and …See details»
Kymab Company Profile - Office Locations, Competitors, Revenue …
Aug 10, 2021 Kymab has 5 employees across 2 locations and $220.4 m in total funding,. See insights on Kymab including office locations, competitors, revenue, financials, executives, …See details»
Kymab - The Org
Kymab is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform …See details»
Kymab: CASE STUDY - Wellcome Sanger Institute
About Kymab . Kymab is a therapeutic antibody company based in Cambridge, UK, developing novel solutions in drug and vaccine development. Using its unique technology with roots in the laboratories of the Wellcome Sanger …See details»
Sanofi completes Kymab acquisition
Apr 9, 2021 Sanofi completes Kymab acquisition. April 9, 2021. Sanofi announced today the successful completion of its acquisition of Kymab Group Ltd., adding KY1005 to its pipeline, a …See details»
Kymab - VentureRadar
Website: http://www.kymab.com. Kymab is a clinical-stage biopharmaceutical company developing a deep pipeline of novel antibody-based therapies in a broad range of ...See details»
Kymab - Funding, Financials, Valuation & Investors - Crunchbase
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics.See details»
Sanofi’s Acquisition of Kymab - MergerSight Group
Mar 10, 2021 Sanofi, the French pharma company born from the merger between Sanofi-Synthelabo and Aventis, has agreed to acquire Kymab, a UK-based clinical-stage biopharmaceutical company, which is concentrating on …See details»
Kymab 2025 Company Profile: Valuation, Investors, Acquisition
Kymab General Information Description. Developer of novel human antibody-based therapies in a broad range of indications. The company offers fully human monoclonal antibody therapeutics …See details»
Kymab - Overview, News & Similar companies | ZoomInfo.com
Jan 11, 2021 Who is Kymab. Founded in 2010, Kymab is a clinical-stage biopharmaceutical company developing a deep pipeline of novel human antibody-based therapies in a broad …See details»
Why Kymab Agreed to be Acquired by Sanofi
Jun 21, 2022 In 2017, Kymab had four therapeutic areas and a large research and translational footprint of 150 people, plus a burgeoning clinical development organization. And the company …See details»
Sanofi gains full global rights to a promising antibody for ...
Jan 11, 2021 (PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French multinational pharmaceutical company Sanofi to acquire Kymab, a clinical-stage …See details»
Sanofi buys Kymab for up to $1.5 billion to expand in …
Jan 11, 2021 French drugmaker Sanofi has agreed to buy British immunotherapy firm Kymab for up to $1.45 billion, the latest in a string of deals as it belatedly expands in a fast-growing …See details»
Sanofi buys UK's Kymab and inflammatory disease hopeful for …
4 days ago Sanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big French pharma seeks to add to its pipeline of drugs that treat inflammatory diseases and cancer.See details»
Sanofi acquires immunotherapy biotech Kymab - Financial Times
Jan 11, 2021 French drugmaker Sanofi has announced a deal of up to $1.45bn to buy UK biotech Kymab and confirmed it is studying the possibility of helping manufacture rival Covid …See details»
Kymab - Bill & Melinda Gates Foundation
Kymab has developed a proprietary mouse platform that contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies.See details»
Kymab signs immuno-oncology deal for bi-specific antibodies
Oct 11, 2016 UK biotech company Kymab is to collaborate with China’s EpimAb Biotherapeutics to develop bispecific antibodies in the immuno-oncology field.See details»